The Therapeutic Effects and Mechanisms of Salidroside on Cardiovascular and Metabolic Diseases: An Updated Review
- PMID: 33991395
- DOI: 10.1002/cbdv.202100033
The Therapeutic Effects and Mechanisms of Salidroside on Cardiovascular and Metabolic Diseases: An Updated Review
Abstract
The increasing incidence of metabolic and cardiovascular diseases has severely affected global human health and life safety. In recent years, some effective drugs with remarkable curative effects and few side effects found in natural compounds have attracted attention. Salidroside (SAL), a phenylpropane glycoside, is the main active ingredient of the plateau plant Rhodiola. So far, many animal experiments proved that SAL has good biological activity against some metabolic and cardiovascular diseases. However, most of these reports are scattered. This review systematically summarizes the pharmacological progress of SAL in the treatment of several metabolic (e. g., diabetes and non-alcoholic fatty liver disease) and cardiovascular (e. g., atherosclerosis) diseases in a timely manner to promote the clinical application and basic research of SAL. Accumulating evidence proves that SAL has beneficial effects on these diseases. It can improve glucose tolerance, insulin sensitivity, and β-cell and liver functions, and inhibit adipogenesis, inflammation and oxidative stress. Overall, SAL may be a valuable and potential drug candidate for the treatment of metabolic and cardiovascular diseases. However, more studies especially clinical trials are needed to further confirm its therapeutic effects and molecular mechanisms.
Keywords: atherosclerosis; cardiovascular disease; diabetes; metabolic disease; salidroside.
© 2021 Wiley-VHCA AG, Zurich, Switzerland.
Similar articles
-
Rhodiola and salidroside in the treatment of metabolic disorders.Mini Rev Med Chem. 2019;19(19):1611-1626. doi: 10.2174/1389557519666190903115424. Mini Rev Med Chem. 2019. PMID: 31481002 Review.
-
Salidroside protects against ox-LDL-induced endothelial injury by enhancing autophagy mediated by SIRT1-FoxO1 pathway.BMC Complement Altern Med. 2019 May 30;19(1):111. doi: 10.1186/s12906-019-2526-4. BMC Complement Altern Med. 2019. PMID: 31146723 Free PMC article.
-
Pharmacological effects of salidroside on central nervous system diseases.Biomed Pharmacother. 2022 Dec;156:113746. doi: 10.1016/j.biopha.2022.113746. Epub 2022 Oct 10. Biomed Pharmacother. 2022. PMID: 36228376 Review.
-
Salidroside - Can it be a Multifunctional Drug?Curr Drug Metab. 2020;21(7):512-524. doi: 10.2174/1389200221666200610172105. Curr Drug Metab. 2020. PMID: 32520682 Review.
-
Salidroside Decreases Atherosclerosis Plaque Formation via Inhibiting Endothelial Cell Pyroptosis.Inflammation. 2020 Apr;43(2):433-440. doi: 10.1007/s10753-019-01106-x. Inflammation. 2020. PMID: 32076940
Cited by
-
Network pharmacology analysis combined with experimental validation to explore the therapeutic mechanism of salidroside on intestine ischemia reperfusion.Biosci Rep. 2023 Aug 31;43(8):BSR20230539. doi: 10.1042/BSR20230539. Biosci Rep. 2023. PMID: 37530723 Free PMC article.
-
Salidroside Ameliorated Intermittent Hypoxia-Aggravated Endothelial Barrier Disruption and Atherosclerosis via the cAMP/PKA/RhoA Signaling Pathway.Front Pharmacol. 2021 Aug 24;12:723922. doi: 10.3389/fphar.2021.723922. eCollection 2021. Front Pharmacol. 2021. PMID: 34504429 Free PMC article.
-
Gut microbiota profiling revealed the regulating effects of salidroside on iron metabolism in diabetic mice.Front Endocrinol (Lausanne). 2022 Sep 23;13:1014577. doi: 10.3389/fendo.2022.1014577. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36213297 Free PMC article.
-
Salidroside Reduced Ca2+-CaM-CAMKII-Dependent eNOS/NO Activation to Decrease Endothelial Cell Injury Induced by Cold Combined with Hypoxia.Cell Biochem Biophys. 2024 Dec;82(4):3477-3487. doi: 10.1007/s12013-024-01434-2. Epub 2024 Jul 17. Cell Biochem Biophys. 2024. PMID: 39020087
-
Ultra-High-Performance Liquid Chromatography-Tandem Mass Spectrometry and Network Pharmacology Reveal the Mechanisms of Rhodiola crenulata in Improving Non-Alcoholic Fatty Liver Disease.Curr Issues Mol Biol. 2025 May 1;47(5):324. doi: 10.3390/cimb47050324. Curr Issues Mol Biol. 2025. PMID: 40699724 Free PMC article.
References
-
- J. B. Meigs, P. W. F. Wilson, C. S. Fox, R. S. Vasan, D. M. Nathan, L. M. Sullivan, R. B. D'Agostino, ‘Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease’, J. Clin. Endocrinol. Metab. 2006, 91, 2906-2912.
-
- D. Giugliano, K. Esposito, ‘Mediterranean diet and metabolic diseases’, Curr. Opin. Lipidol. 2008, 19, 63-68.
-
- T. Ioanna, E. Paul, K. Vasilis, E. Majid, ‘Worldwide exposures to cardiovascular risk factors and associated health effects: Current knowledge and data gaps’, Circulation 2016, 133, 2314-2333.
-
- F. Kanwal, J. R. Kramer, L. Li, J. Dai, Y. Natarajan, X. Yu, S. M. Asch, H. B. El-Serag, ‘Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease’, Hepatology 2020, 71, 808-819.
-
- R. Scaglione, C. Argano, T. D. Chiara, G. Licata, ‘Obesity and cardiovascular risk: the new public health problem of worldwide proportions’, Expert Rev. Cardiovasc. Ther. 2004, 2, 203-212.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical